Vascular responses as therapeutic targets after SCI
Vascular responses as therapeutic targets after SCI
批准号:
6820940
负责人:
THEO HAGG
金额:
$33.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-05-03 至 2009-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Contusive spinal cord injury (SCI) causes local endothelial cell damage, resulting in vascular leakage and edema and the initiation of inflammation. These processes may lead to later tissue loss and functional deficits. Vascular endothelial growth factor (VEGF) is induced by SCI and may contribute to the leakage. VEGF may initiate detrimental processes, as we have shown that VEGF injections after SCI in adult rats increases tissue loss seen at six weeks. Pharmacological inhibition of VEGF reduces edema, inflammation and tissue loss in stroke models. Angiopoietin 1 (Ang1) induces vessel maturation and reduces leakage in many systems and is reduced after SCI. Therefore, in aim la, a VEGF trap and/or Ang1 will be administered early after SCI to test whether reduction of early leakage, edema and inflammation reduces later loss of selected white matter tracts. In aim lb) the contribution of endothelial cell loss to secondary damage will be evaluated by protecting the cells with Ang1 plus VEGF or integrin agonist, as these can promote endothelial cell survival in vitro. From 3-7 days after SCI, an angiogenic response occurs in the injured cord. New vessels may counteract degeneration by increased tissue perfusion, while their leakage may cause damage. Thus, in aim 2a, Ang1, will be administered during the angiogenic phase to promote maturation and maintenance of the new vasculature, possibly resulting in better tissue protection. The new blood vessels regress between day 7 and 14 as secondary spinal tissue loss (cavitation) begins. This angiogenic failure may contribute to the secondary damage. In aim 2b, the protective effects of maintaining the new blood vessels will be assessed by treating with Ang1 plus VEGF or Ang1 plus integrin agonist. The central hypothesis is that by enhancing stable and mature angiogenesis we will ultimately be able to reduce loss of important white matter tracts and improve functional sensory and motor outcome after SCI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational assessment of an FAK inhibitor for acute cerebroprotection
-
批准号:10673417
-
项目类别:
-
资助金额:$30.18万
-
财政年份:2023
-
负责人:THEO HAGG
-
依托单位:
Targeting blood-derived integrin signaling after stroke
-
批准号:10392926
-
项目类别:
-
资助金额:$32.38万
-
财政年份:2018
-
负责人:THEO HAGG
-
依托单位:
Targeting blood-derived integrin signaling after stroke
-
批准号:10155592
-
项目类别:
-
资助金额:$32.38万
-
财政年份:2018
-
负责人:THEO HAGG
-
依托单位:
Targeting blood-derived integrin signaling after stroke
-
批准号:9923009
-
项目类别:
-
资助金额:$32.38万
-
财政年份:2018
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:10619621
-
项目类别:
-
资助金额:$42.87万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:7891162
-
项目类别:
-
资助金额:$29.44万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:7483182
-
项目类别:
-
资助金额:$29.73万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:8099417
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:7315601
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:10406347
-
项目类别:
-
资助金额:$42.87万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:8722255
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:7626316
-
项目类别:
-
资助金额:$29.73万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Targeting CNTF to increase adult forebrain neurogenesis
-
批准号:10058346
-
项目类别:
-
资助金额:$42.87万
-
财政年份:2007
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:6891637
-
项目类别:
-
资助金额:$33.68万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:7243356
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:8512805
-
项目类别:
-
资助金额:$41.11万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:8885911
-
项目类别:
-
资助金额:$42.6万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:7051958
-
项目类别:
-
资助金额:$33.16万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:8699847
-
项目类别:
-
资助金额:$42.18万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
Vascular responses as therapeutic targets after SCI
-
批准号:7900479
-
项目类别:
-
资助金额:$60.55万
-
财政年份:2004
-
负责人:THEO HAGG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
BCAR1在非小细胞肺癌中作为肿瘤血管生成"失稳分子"的相关研究
-
批准号:81101782
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:邓波
-
依托单位:
Shh信号通路在脑梗塞中双重调控血管新生和血管渗漏的作用及机制研究
-
批准号:81070938
-
项目类别:面上项目
-
资助金额:36.0万元
-
批准年份:2010
-
负责人:胡波
-
依托单位:
益肺清化颗粒对血管生成因子及VEGF/KDR和Angiopoietins /Tie2信号传导通路的调控作用研究
-
批准号:30973841
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:周斌
-
依托单位:
血管发育调控基因的变异对动脉性血管疾病的影响
-
批准号:30670862
-
项目类别:面上项目
-
资助金额:27.0万元
-
批准年份:2006
-
负责人:张伟丽
-
依托单位: